MB-106 induces response in indolent lymphoma
Click Here to Manage Email Alerts
An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.
MB-106 (Mustang Bio) is a CD20-targeted, autologous CAR T-cell therapy.
A five-center, three-arm phase 1/phase 2 trial is evaluating MB-106 for treatment of relapsed or refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma, including follicular lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma.
All four patients with relapsed or refractory non-Hodgkin lymphoma treated at the starting dose of 3.3 x 106 CAR T cells/kg responded to therapy.
The responders included two patients with follicular lymphoma who achieved complete response, a patient with Waldenström macroglobulinemia who had received nine prior treatments, and a patient diagnosed with hairy cell leukemia variant who had been heavily transfusion dependent.
After treatment of these four patients, the safety review committee approved escalating the dose to 1 x 107 CAR T cells/kg.
Researchers reported persistence of CAR T cells at 6 months and beyond, according to a Mustang Bio press release.
Safety data also appeared favorable, according to investigators, with cytokine release syndrome cases limited to grade 1.
Up to 18 patients are expected to be treated in each phase 1 arm, with six patients treated at the maximum tolerated dose in each arm.
The phase 2 portion will include specific arms of patients with relapsed or refractory CD20-positive B-cell hematologic malignancies. Patients will be treated at the recommended phase 2 dose for their respective arms.
“MB-106 continues to show potential as an immunotherapy option for patients with a wide range of hematologic malignancies, including patients previously treated with CD19-directed CAR-T cell therapy,” study chair Mazyar Shadman, MD, MPH, associate professor and physician at Fred Hutch and University of Washington, said in the release. “We are excited that the first data from the expanded evaluation of MB-106 are similar in safety as what we’ve seen to date in [an] ongoing phase 1/2 clinical trial at Fred Hutch. Additionally, the data from the ongoing clinical trial at Fred Hutch continue to demonstrate a high rate of complete and durable responses.”
Collapse
Press Release
Click Here to Manage Email Alerts